Abstract
Prompt localization of infection sites is essential for initiating appropriate therapeutic measures. There have been major advances in the management of patients suffering from infective and/or inflammatory disorders as a result of introduction of newer drugs with high sensitivity and specificity. Since the last decade, 99mTc-ciprofloxacin was used as a biologically active radiopharmaceutical to diagnose inflammation but it has some problems related to radiochemical purity and stability. The aim of this study is to develop simple and easy formulation of cefoperazone (other broad spectrum antimicrobial agent) with 99mTc a ready to use labeling kit for infection imaging. The optimum condition that gives high labeling yield of 99mTc-cefoperazone complex, 97.9%, was achieved by using 3 mg cefoperazone, 100 μg Sn(II), at pH 8 and 10-minute reaction time. For in vivo binding of 99mTc-cefoperazone pharmacokinetic studies were carried in experimentally induced infection, in the left thigh, using Staphylococcus aureus in rats. Both thighs of the rats were dissected and counted and the ratio of bacterial infected thigh/contralateral thigh was then evaluated. The time for maximum accumulation of 99mTc-cefoperazone at the site of infection (T/NT = 4.5) was 45-minute post intravenous injection, followed by gradual decline. So, 99mTc-cefoperazone complex is simple and stable preparation for infection imaging after 45-minute post injection.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
J. E. T. Lima, C. Maliska, M. R. B. Goncalves, R. C. Lima, R. Corbo, World J. Nucl. Med., 3 (2004) 284.
K. E. Britton, S. Vinjamuri, A. V. Hall et al., Eur. J. Nucl. Med., 24 (1997) 553.
J. E. Seabold, C. J. Palestro, M. L. Brown et al., J. Nucl. Med., 38 (1997) 994.
E. V. Staab, H. McCartney, Semin. Nucl. Med., 8 (1978) 219.
J. E. Seabold, L. A. Forstrom, D. S. Schauwecher et al., J. Nucl. Med., 38 (1997) 997.
M. D. Schrijver, K. Streule, R. Senekowitsch et al., Nucl. Med. Commun., 8 (1987) 895.
J. R. Buscombe, R. F. Miller, D. Lui et al., Nucl. Med. Commun., 12 (1991) 583.
J. G. McAfee, G. Gagne, G. Subramanian et al., J. Nucl. Med., 32 (1991) 2126.
M. S. Akhtar, A. Qaisar, J. Irfanullah et al., J. Nucl. Med., 46 (2005) 567.
M. S. Akhtar, J. Iqbal, M. A. Khan et al., J. Nucl. Med., 45 (2004) 849.
P. H. Nibbering, M. M. Welling, A. Paulusma-Annema et al., J. Nucl. Med., 45 (2004) 321.
C. J. Van Der Laken, O. C. Boerman, J. G. Oyen et al., Eur. J. Nucl. Med., 25 (1998) 535.
K. E. Britton, S. Vinjamuri, A. V. Hall et al., Eur. J. Nucl. Med., 24 (1997) 553.
I. Pirmettis, G. S. Limouris, M. Papadopoulos et al., Eur. J. Nucl. Med., 26 (1999) 1108.
S. Vinjamuri, A. V. Hall, K. K. Solanki, Lancet, 347 (1996) 233.
H. S. Rien, J. R. Huub, C. B. Otto, D. Rudi, S. Guido, J. Nucl. Med., 45 (2004) 2088.
J. O. seung, S. R. Jin, W. S. Joong, J. Y. Eun, J. H. Hyun et al., Appl. Radiation Isotopes, 57 (2002) 193.
I. Kleisner, P. Komarek, I. Komarkova, M. Konopkova, Nuklearmedizin, 41 (2002) 224.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Motaleb, M.A. Preparation of 99mTc-cefoperazone complex, a novel agent for detecting sites of infection. J Radioanal Nucl Chem 272, 167–171 (2007). https://doi.org/10.1007/s10967-006-6754-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-006-6754-y